BioWorld

Nov. 18, 2010

Roche Steps Back from RNA Interference, Cuts 6% of Staff

As part of a cost-cutting corporate restructuring, Roche AG plans to discontinue its preclinical research in the area of RNA interference (RNAi) at sites in Kulmbach, Germany; Madison, Wisc.; and Nutley, N.J. (BioWorld Today) Read More

Avanir Raising $88M Post-Nuedexta Approval

From 'FAB' to Flush: Sutro Adding $36.5M in Series C

Investors Hammer Resverlogix Over Cholesterol Drug Data

Forma Will Get $20M from Eisai in Drug Discovery Deal

Clinic Roundup

Stock Movers

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

Vitesse finesse pays off: DBV wins in peanut allergy phase III

BioWorld

DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....

Harbour Biomed closes busy year with $1B+ BMS deal

BioWorld

Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies....

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...